Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tutogen Medical, Inc. (OTCBB: TTGN) -- Ignore unavailable to you. Want to Upgrade?

To: leigh aulper who wrote (44)	12/10/2001 10:50:29 AM
From: leigh aulper	Respond to of 56

Tutogen Medical Reports 4th Quarter Revenues and FY 2001 Results CLIFTON, N.J.--(BUSINESS WIRE)--Dec. 10, 2001--Tutogen Medical, Inc. (AMEX: TTG) ("Tutogen") today reported revenue for the 4th quarter and Fiscal Year 2001. Results for the 4th Quarter of the Fiscal Year 2001 were $ 3.3 million vs. $ 3.5 million for the same period last year. Fiscal Year 2001 revenues were $ 13.2 million vs. $ 16.6 million last year. Net loss for Fiscal Year 2001 was $ 0.7 million or $ .05 loss per basic share compared to a net income of $ 2.8 million or $ .24 earnings per basic share and $ .20 earnings per share fully diluted in 2000. Although the results reflect a loss for the most recent fiscal year, Tutogen's cash position has improved from $ 3.8 million to $ 4.3 million over the past year. In addition, revenues for the first quarter of Fiscal Year 2002, beginning on October 1st, are expected to reflect a revenue increase of more then 40% from what the Company reported in the fourth quarter of Fiscal Year 2001. Manfred Krueger, President and CEO of Tutogen, commented on the results: "We previously have reported to our shareholders that Fiscal Year 2001 would be a transitional year for our Company as we laid the groundwork for the launch of new biologic solutions for the spine, dental and urological markets. That work is now behind us, and we already are seeing a significant revenue increase during the first quarter of this fiscal year. I am confident that we will experience greater market penetration for Tutogen's biological implants in 2002 and beyond. We expect to return to profitability this year." Tutogen Medical, Inc. utilizes its patented Tutoplast(R) process of tissue preservation and viral inactivation, to manufacture bioimplants for neurosurgical, orthopedic, reconstructive and general surgical indications. The Company's Tutoplast(R) products are sold and distributed worldwide by the Mentor Corporation (NMS: MNTR), Sulzer Medica (NYSE: SM), IOP, Inc. and through subsidiaries in the U.S. and Germany.